Therapeutic Effects of SB 365 Natural Aticancer Drug for Various Cancers with Advanced Stages in 7 Years
2021
SB is a root extract of plant Pusatilla koreana, used traditionally as an useful antiinflammatory and antitumor agent in South Korea for long times. From March 2013 to December 2019, for 7 years there were 421 consecutive advanced and recurrent various kinds of cancer patients for intensified SB 365 anticancer drug treatment. Two important components, Pulsatilla saponin D is the most effective saponin with cancer cell apoptosis, deoxypodophyllotoxin inhibits new blood vessel formation, and anti-inflammatory effects with immune potentiative activities were confirmed. Cancer studied firstly in pancreas, followed by stomach, large intestine, lung, bile duct, liver, breast, kidney, uterus, oral cavity, esophagus and prostate. Almost of cancers were advanced and recurred status. Intravenous administration was done with intratumoral injection, intraperitoneal or intrathoracic administrations were done with change position, and inhalation therapy was also done. Side effects were clinically insignificant, most commonly fever, chills, nextly injection site pain, erythema, itching, nausea and vomitings were developed. 73.6% of total patients received 1-2 cycles of chemotherapies only, 3 cycles received patient survived for 6 months, 6 cycles survived for 12 months, and 9 cycles or more survived 30 months of survival durations. Pain control with improved appetite and immunity were noted as SB 365 treatments were going on. It is strongly requested to regain the permission of Korean FDA and prompt supports of the national medical insurance, that makes remarkable survival duration and for lesser economic burdons for advanced, recurrent cancer patients and save the funds of national medical insurance. And also highly recommended to make SB treatment available in foreign cancer patients for economic advantages and national image promotions.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI